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Abstract
Background: Several studies have shown associations between hyperglycemia and risk of cardiovascular disease (CVD) and
mortality, yet glucose-lowering treatment does little to mitigate this risk. We examined whether associations between
hyperglycemia and CVD risk were explained by underlying insulin resistance.
Methods: In 60 middle-aged individuals without diabetes we studied the associations of fasting plasma glucose, 2-hour
post oral glucose tolerance test plasma glucose, insulin sensitivity as well as body fat percentage with CVD risk. Insulin
sensitivity was measured as the glucose infusion rate during a euglycemic hyperinsulinemic clamp, body fat percentage was
measured by dual X-ray absorptiometry, and CVD risk was estimated using the Framingham risk score. Associations of
fasting plasma glucose, 2-hour plasma glucose, insulin sensitivity and body fat percentage with the Framingham risk score
were assessed in linear regression models.
Results: Both fasting and 2-hour plasma glucose levels were associated with higher Framingham risk score (fasting glucose:
r
2=0.21; 2-hour glucose: r
2=0.24; P,0.001 for both), and insulin sensitivity with lower Framingham risk score (r
2=0.36;
P,0.001). However, adjustment for insulin sensitivity and 2-hour glucose made the effect of fasting glucose non-significant
(P=0.060). Likewise, when adjusting for insulin sensitivity and fasting glucose, the association between 2-hour glucose and
Framingham risk score disappeared (P=0.143). In contrast, insulin sensitivity was still associated with Framingham risk score
after adjusting for glucose levels (P,0.001). Body fat was not associated with Framingham risk score when taking insulin
sensitivity into account (P=0.550).
Conclusion: The association between plasma glucose levels and CVD risk is mainly explained by insulin resistance, which
raises the question of whether glucose lowering per se without changes in the processes that underlie hyperglycemia
should be the sole clinical paradigm in the treatment of type 2 diabetes or its prevention.
Citation: Færch K, Bergman B, Perreault L (2012) Does Insulin Resistance Drive the Association between Hyperglycemia and Cardiovascular Risk? PLoS ONE 7(6):
e39260. doi:10.1371/journal.pone.0039260
Editor: Melania Manco, Scientific Directorate, Bambino Hospital, Italy
Received March 16, 2012; Accepted May 22, 2012; Published June 15, 2012
Copyright:  2012 Færch et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The National Institutes of Health (DK064811, DK059739, RR00036) and Fonden til Lægevidenskabens Fremme funded this work. The funders had no
role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: KF is employed by Steno Diabetes Center A/S, a research
hospital working in the Danish National Health Service and which is owned by Novo Nordisk A/S. Steno Diabetes Center A/S receives part of its core funding from
unrestricted grants from the Novo Nordisk Foundation and Novo Nordisk A/S. K.F. owns shares in Novo Nordisk A/S. No other potential conflicts of interest
relevant to this article were reported. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: krif@steno.dk
Introduction
Type 2 diabetes significantly increases the risk for cardiovascu-
lar disease (CVD) and all-cause mortality. People with diabetes
without prior myocardial infarction and people with a prior
myocardial infarction, but without diabetes, have similar risk of
survival [1], and therefore many consider diabetes as a CVD
equivalent. Numerous trials have studied effects of intensive
glucose-lowering treatment in patients with diabetes, but the
results have not been convincing in terms of lowering short-term
CVD risk and survival [2–4]. These observations raise the
question of whether glucose lowering per se without changes in
the processes that underlie hyperglycemia (ie. insulin resistance
and/or beta cell failure) should be the sole clinical paradigm in the
treatment of type 2 diabetes or its prevention.
Fasting and post-challenge glucose levels do not confer the same
risk of CVD disease and mortality. A meta-analysis of several
observational studies showed that the association of CVD risk with
post-challenge glucose concentration is stronger than that of
fasting plasma glucose [5]. These data are supported by the
Diabetes epidemiology: collaborative analysis of diagnostic criteria
in Europe (DECODE), which showed that 2-hour glucose, but not
fasting glucose, predicts CVD mortality in individuals with glucose
levels within the normal range [6]. However, it is still unknown
which underlying metabolic abnormalities that cause the increased
CVD risk in people with elevated 2-hour glucose. Since 2-hour
glucose is closely related to peripheral insulin resistance and lack of
beta cell compensation [7], insulin resistance is likely to be the link.
This suggestion is supported by the European Group for the Study
of Insulin Resistance: relationship between insulin sensitivity and
cardiovascular disease risk (EGIR-RISC) collaboration, which
prospectively evaluates the role of insulin resistance in CVD risk
[8]. Also the fact that insulin resistance often clusters with other
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hypertension and dyslipidemia [9], makes insulin resistance likely
to be responsible for the higher CVD risk in hyperglycemic
individuals.
Using the euglycemic hyperinsulinemic clamp in 60 middle-
aged individuals without diabetes, we examined whether associa-
tions between hyperglycemia and CVD risk were explained by
underlying insulin resistance.
Materials and Methods
Study population
Data used in this study originate from 3 separate studies that
enrolled a total of 60 American men and women without diabetes.
Of these, 34 had normal glucose tolerance, 10 had isolated
impaired fasting glucose, 6 had isolated impaired glucose
tolerance, and 10 had combined impaired fasting glucose and
impaired glucose tolerance [10]. BMI ranged from 20.1–41.6 kg/
m2 in those with NGT, from 27.8–40.7 kg/m2 in those with i-
IFG, from 27.0–37.6 kg/m2 in those with i-IGT and from 24.3–
36.8 kg/m2 in those with IFG+IGT. All study procedures took
place at the Clinical Translational Research Center at the
University of Colorado Anschutz Medical Campus, Aurora, CO,
USA between 2004 and 2012.
The studies were performed in accordance with the Helsinki
declaration and approved by the Colorado Multiple Institutional
review Board. Informed written consent was obtained from all
participants prior to the studies.
Study procedures
Oral glucose tolerance test. A standard 75 g oral glucose
tolerance test (OGTT) was performed after an overnight fast.
Blood samples for measurement of plasma glucose were drawn in
the fasting state and 120 min after ingestion of glucose.
Euglycemic hyperinsulinemic clamp. On a separate day,
peripheral insulin sensitivity was measured by a euglycemic
hyperinsulinemic clamp. After an overnight fast, basal blood
samples were taken and a 2-hour basal period was initiated. After
the basal period, a 2-hour euglycemic hyperinsulinemic clamp at
40 mU/m
2/min was performed as described previously [11,12].
Insulin sensitivity was assessed as the mean glucose infusion rate
during the last 30 min of the insulin-stimulated steady state period.
Cardiovascular risk. CVD risk was calculated using the
Framingham risk score, which includes information on gender,
age, total and high-density lipoprotein (HDL) cholesterol, diastolic
and systolic blood pressure, as well as diabetes and smoking status
[13]. Systolic and diastolic blood pressures were measured with the
participants in the supine position. Blood samples for measure-
ment of total cholesterol and high-density lipoprotein were taken
after an overnight fast. Absolute 10-year risk (%) of developing
coronary heart disease (CHD) was calculated, and participants
were divided into four categories of risk (very low, low, moderate,
and high).
Body composition. Body fat percentage and fat-free mass
(FFM) was determined by dual-energy X-ray absorptiometry.
Laboratory analyses
Plasma glucose concentration was analyzed using the hexoki-
nase/G6P-DH technique (Roche Diagnostics, Mannheim, Ger-
many). Serum insulin concentration was analyzed by a radioim-
munoassay (Linco Research Inc., St. Louis, MO). Plasma
cholesterol and triglyceride concentrations were measured enzy-
matically using commercially available kits (Beckman Coulter,
Inc., Brea, CA).
Statistical analysis
Linear regression models were used to study the relationships
between CVD risk and fasting glucose, 2-hour glucose, insulin
sensitivity and body fat percentage. Because absolute 10-year risk
of CHD was not linearly related to the measures of glucose
metabolism, Framingham risk score was used as outcome in the
models. Measures of glucose metabolism and body fat were
standardized before analysis to be able to compare the effect size of
the different measures on CVD risk. The analyses were performed
with and without adjustment for insulin sensitivity, glucose levels
and body fat percentage. None of the analyses were adjusted for
age and gender, since these were part of the Framingham risk
score. All statistical analyses were performed using SAS version 9.1
and P,0.05 was considered statistically significant.
Results
Clinical characteristics
Clinical characteristics of the study population are shown in
Table 1. The population had a wide range of age and obesity,
markers of glucose metabolism (fasting glucose, 2-hour glucose and
insulin sensitivity) as well as cardiovascular risk factors (Framing-
ham risk score, total cholesterol and HDL cholesterol).
Plasma glucose levels and Framingham risk score
Both fasting and 2-hour glucose levels were highly significantly
related to the Framingham risk score (P,0.001 for both;
Figure 1A–B); however, the correlations were not very strong
(fasting glucose: r
2=0.24; 2-hour glucose=r
2=0.21). Beta coeffi-
cients from the linear regression analyses of Framingham risk score
with fasting and 2-hour glucose are shown in Figure 2A–B. The
effect sizes correspond to absolute changes in the Framingham risk
score per 1 SD increase in the plasma glucose level. In the
unadjusted model, 1 SD increase in fasting glucose (,1.4 mmol/
L) was significantly associated with 6.8-point higher Framingham
risk score (P,0.001; Figure 2A). After adjustment for insulin
Table 1. Clinical characteristics of the 60 study participants.
Men (%) 50
Age (years) 53.0 (41.5;60.5)
BMI (kg/m
2) 29.5 (26.2;32.7)
Body fat (%) 33.8 (26.3;41.2)
Fasting plasma glucose (mmol/L) 5.2 (4.9;5.7)
2-hour plasma glucose (mmol/L) 5.7 (4.9;7.9)
Glucose infusion rate (mg/min/kg FFM) 4.6 (2.5;7.4)
Systolic blood pressure (mmHg) 132 (121;142)
Diastolic blood pressure (mmHg) 80 (73;85)
Total cholesterol (mmol/L) 4.9 (4.4;5.6)
High-density lipoprotein (mmol/L) 1.2 (0.9;1.4)
Framingham score 7 (2;10)
Absolute 10-year risk of CHD (%) 8 (4;16)
Categories of CHD risk (%)
Very low risk of CHD (,10%) 51.7
Low risk of CHD ($10 and ,15%) 20.0
Moderate risk of CHD ($15 and ,20%) 10.0
High risk of CHD ($20%) 18.3
Data are medians (IQR) or percentages. FFM: Fat-free mass.
doi:10.1371/journal.pone.0039260.t001
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score per SD increase in fasting glucose (P=0.023), and further
adjustment for 2-hour glucose made the association non-significant
(P=0.060; Figure 2A). There was a highly significant association
between 2-hour glucose and Framingham risk score; 1 SD increase
in 2-hour glucose (,3.3 mmol/L) corresponded to a 5.2-point
increase in the Framingham risk score (P,0.001; Figure 2B).
However, adjustment for insulin sensitivity reduced the strength of
the association (P=0.051), and further adjustment for fasting
glucose completely abolished the association (P=0.143; Figure 2B).
Adjustment for body fat did not change the associations of
fasting and 2-hour glucose with the Framingham risk score
(Figure 2A–B).
Insulin sensitivity and Framingham risk score
Insulin sensitivity was more strongly related to the Framingham
risk score than were fasting and 2-hour glucose levels (r
2=0.36,
P,0.001, Figure 1C). One SD increase in insulin sensitivity
(,3.7 mg/min/kg FFM) was significantly associated with a 3.9-
points reduction in the Framingham risk score (Figure 2C).
Adjustment for body fat percentage, fasting and 2-hour glucose did
only change this association slightly (P=0.005).
Body fat percentage and Framingham risk score
Body fat was significantly related to the Framingham risk score
in the unadjusted model, but the correlation was very weak
(r
2=0.12; P=0.006; Figure 1D); 1 SD increase in body fat
percentage (,9.4%-points) corresponded to 2.2-points higher
Framingham risk score (Figure 2D). No association between body
fat and Framingham risk score was observed after adjustment for
insulin sensitivity (P=0.550) or additionally plasma glucose levels
(P=0.492).
Discussion
Several studies have demonstrated relationships of plasma
glucose levels with CVD and mortality [6,14–17], yet glucose-
lowering treatment does little to mitigate this risk. In this study we
hypothesized that underlying insulin resistance drives the associa-
tions between glycemia and CVD risk. By using gold standard
measures of insulin sensitivity, we demonstrated that insulin
resistance is largely responsible for the relationship between
plasma glucose levels and CVD risk. We also showed that insulin
resistance independent of plasma glucose levels and obesity is
strongly associated with CVD risk as estimated by the Framing-
ham risk score.
Over the past decades, a considerable number of intervention
studies have focused on the role of glucose-lowering strategies on
CVD morbidity and mortality in patients with type 2 diabetes [2–
4]. The results from these trials have only shown limited beneficial
short-term effects of intensive glucose-lowering treatment. Two
large trials did not show beneficial effects of 5-years intensive
Figure 1. Associations between the Framingham risk score and fasting plasma glucose, 2-hour plasma glucose, insulin sensitivity
and body fat percentage. FFM: fat-free mass.
doi:10.1371/journal.pone.0039260.g001
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[2,3]. Moreover, the Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial demonstrated that intensive lowering of
glycemia increased mortality and did not reduce major CVD
events [4]. A 10-year follow-up of the UK Prospective Diabetes
Study (UKPDS) did show beneficial effects of treatment with
sulfonylurea and insulin on CVD and deaths from any cause.
However, of interest, patients only treated with the insulin-
sensitizing agent metformin seemed to have at least at as favorable
effects as those treated with sulfonylurea and insulin [18].
Our results indicate that lowering hyperglycemia without
changing the underlying processes that cause hyperglycemia may
not be the optimal way of reducing CVD risk. Thus, treatment
modalities for improvement of insulin resistance may be more
efficient both in terms of reducing CVD risk and improving
glycemic control. Indeed, there are indications that treatment
strategies focused on improving insulin sensitivity have beneficial
effects on CVD risk factors and events. The Actos Now for
Prevention of Diabetes (ACT NOW) study showed beneficial
effects of the insulin-sensitizing agent pioglitazone on carotid
intima-media thickness in individuals with impaired glucose
tolerance [19]. Also the PROspective pioglitAzone Clinical Trial
In macro-Vascular Events (PROactive) [20] and the Pioglitazone
Effect on Regression of Intravascular Sonographic Coronary
Obstruction Prospective Evaluation (PERISCOPE) [21] showed
that treatment with pioglitazone decreased major CVD events and
progression of atherosclerosis in type 2 diabetes patients with pre-
existing CVD. In addition to these pharmacological trials,
beneficial effects of intensive lifestyle-modification on CVD risk
factors have been observed both in individuals with diabetes and
pre-diabetes [22,23].
To our knowledge, this is the first study to address whether gold-
standard-measured insulin sensitivity drives the association
between glycemia and CVD risk. In the San Antonio Heart
Study, insulin resistance as measured by the homeostasis model
assessment (HOMA-IR) was related to CVD risk factors, whereas
insulin secretion was not [24]. Interestingly, they also found that
insulin-sensitive individuals who developed diabetes during 7-years
of follow-up had a CVD risk similar to people who did not develop
diabetes [24]. This indicates that hyperglycemia per se was not
related to CVD risk. This finding is in accordance with a recent
study showing that physical activity reduces the risk of CVD death
and all-cause mortality across a wide spectrum of glycemic control
including people with diabetes [25]. The authors found that
physically active individuals with hemoglobin A1c (HbA1c) levels
$7% did not have increased risk of CHD or mortality. The long-
term effects of insulin resistance on CVD risk is currently being
investigated in the EGIR-RISC study [8].
We found that insulin sensitivity as measured by the clamp
technique explained more of the relationship between 2-hour
glucose and Framingham risk score than between fasting glucose
and Framingham risk score. The reason for this may be related to
the underlying physiology of fasting and post-OGTT hyperglyce-
mia. Elevated 2-hour glucose is mainly related to peripheral
insulin resistance and beta cell decompensation, whereas elevated
fasting glucose is predominantly caused by hepatic insulin
Figure 2. Beta coefficients for relationships between Framingham risk score and fasting plasma glucose, 2-hour plasma glucose,
insulin sensitivity and body fat percentage. Beta coefficients reflect the absolute change in Framingham risk score per SD unit increase in the
explanatory variables.
doi:10.1371/journal.pone.0039260.g002
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sensitivity estimated by the clamp technique predominantly
reflects peripheral insulin sensitivity [26], which may explain
why it does not fully account for the association between fasting
glucose and CVD risk. Future studies may address whether
adjustment for hepatic insulin sensitivity further deteriorates the
association between fasting glucose and risk of CVD.
There are several limitations related to the current study. First,
because of the cross-sectional nature of this study we cannot
determine whether insulin sensitivity in fact is related to future
CVD outcomes. Second, because we did not measure beta cell
function in the entire study population, we cannot exclude
disturbances of insulin secretion being responsible for part of the
observed findings. Third, the use of the Framingham risk score has
several limitations. In general, risk engines are thought to
underestimate risk in women compared with men [27]. Moreover,
the Framingham risk score does not predict CHD risk equally in
all ethnic groups [28]. It has also been suggested that the diabetes-
specific UKPDS risk engine has several advantages over the
Framingham risk score, because it includes a measure of glycemia
(HbA1c) as well as diabetes duration in addition to the traditional
risk factors [29]. However, a systematic review demonstrated that
there is not evidence to suggest that diabetes-specific risk
assessment tools are superior to risk engines developed in the
general population [30]. Moreover, since we estimated CVD risk
in people without diabetes, the Framingham risk score seems to be
a better choice than the UKPDS risk engine. Of note, both the
UKPDS and the Framingham risk score overestimate absolute
CVD risk as compared to observed CVD outcomes, but the ability
of the equations to rank individuals according to CVD risk seems
to be modest [31], which is of importance in this particular study.
In summary, we demonstrated that insulin resistance is re-
sponsible for a large part of the associations between plasma
glucose levels and CVD risk. If these data are confirmed in other
larger prospective studies, markers of insulin resistance (beyond
glucose) should be explored for their clinical utility in high-risk
individuals before the onset of diabetes.
Acknowledgments
We owe the success of this work to the research participants who
volunteered their time to participate and to the committed staff of the the
Clinical Translational Research Center, University of Colorado Anschutz
Medical Campus. K.F. is the guarantor of this work, had full access to all
the data, and takes full responsibility for the integrity of data and the
accuracy of data analysis.
Author Contributions
Conceived and designed the experiments: KF LP. Performed the
experiments: BB LP. Analyzed the data: KF BB LP. Contributed
reagents/materials/analysis tools: BB LP. Wrote the paper: KF.
References
1. Haffner SM, Lehto S, Ro ¨nnemaa T, Pyo ¨ra ¨la ¨ K, Laakso M (1998) Mortality
from Coronary Heart Disease in Subjects with Type 2 Diabetes and in
Nondiabetic Subjects with and without Prior Myocardial Infarction. New
Engl J Med 339: 229–234.
2. Zoungas S, de Galan BE, Ninomiya T, Grobbee D, Hamet P, et al (2009)
Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose
Control on Macrovascular and Microvascular Outcomes in Patients With Type
2 Diabetes. Diabetes Care 32: 2068–2074.
3. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, et al. (2009) Glucose
Control and Vascular Complications in Veterans with Type 2 Diabetes. New
Engl J Med 360: 129–139.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group (2008)
Effects of Intensive Glucose Lowering in Type 2 Diabetes. New Engl J Med 358:
2545–2559.
5. Kodama S, Saito K, Tanaka S, Horikawa C, Fujiwara K, et al. (2012) Fasting
and Post-Challenge Glucose as Quantitative Cardiovascular Risk Factors: A
Meta-Analysis. J Atheroscler Thromb (http://dx.doi.org/10.5551/jat.10975).
6. Ning F, Tuomilehto J, Pyo ¨ra ¨la ¨ K, Onat A, So ¨derberg S, et al (2010)
Cardiovascular Disease Mortality in Europeans in Relation to Fasting and 2-h
Plasma Glucose Levels Within a Normoglycemic Range. Diabetes Care 33:
2211–2216.
7. Færch K, Borch-Johnsen K, Holst JJ, Vaag A (2009) Pathophysiology and
aetiology of impaired fasting glycaemia and impaired glucose tolerance: does it
matter for prevention and treatment of type 2 diabetes? Diabetologia 52: 1714–
1723.
8. Hills SA, Balkau B, Coppack SW, Dekker JM, Mari A, et al. (2004) The EGIR-
RISC STUDY (The European group for the study of insulin resistance:
relationship between insulin sensitivity and cardiovascular disease risk): I.
Methodology and objectives. Diabetologia 47: 566–570.
9. DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome
responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic
cardiovascular disease. Diabetes Care 14: 173–194.
10. American Diabetes Association (2012) Diagnosis and Classification of Diabetes
Mellitus. Diabetes Care 35: S64–S71.
11. Perreault L, Lavely JM, Bergman BC, Horton TJ (2004) Gender differences in
insulin action after a single bout of exercise. J Appl Physiol 97: 1013–1021.
12. Perreault L, Bergman BC, Playdon MC, la-Man C, Cobelli C, et al. (2008)
Impaired fasting glucose with or without impaired glucose tolerance: progressive
or parallel states of prediabetes? Am J Physiol Endocrinol Metab 295: E428–
E435.
13. D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, et al. (2008)
General Cardiovascular Risk Profile for Use in Primary Care. Circulation 117:
743–753.
14. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, et al. (2000)
Association of glycaemia with macrovascular and microvascular complications of
type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405–
412.
15. DECODE Study Group (2001) Glucose tolerance and cardiovascular mortality:
comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161: 397–
405.
16. De Vegt F, Dekker JM, Ruhe HG, Stehouwer CDA, Nijpels G, et al. (1999)
Hyperglycaemia is associated with all-cause and cardiovascular mortality in the
Hoorn population: The Hoorn study. Diabetologia 42: 926–931.
17. Smith NL, Barzilay JI, Shaffer D, Savage PJ, Heckbert SR, et al. (2002) Fasting
and 2-hour postchallenge serum glucose measures and risk of incident
cardiovascular events in the elderly: the Cardiovascular Health Study. Arch
Intern Med 162: 209–216.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-Year
Follow-up of Intensive Glucose Control in Type 2 Diabetes. New Engl J Med
359: 1577–1589.
19. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, et al. (2011)
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. New
Engl J Med 364: 1104–1115.
20. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, et
al. (2005) Secondary prevention of macrovascular events in patients with type 2
diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In
macroVascular Events): a randomised controlled trial. Lancet 366: 1279–1289.
21. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, et al. (2008) Comparison
of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in
Patients With Type 2 Diabetes. JAMA 299: 1561–1573.
22. Neiberg RH, Wing R, Bray GA, Reboussin DM, Rickman AD, et al. (2012)
Patterns of Weight Change Associated with Long-Term Weight Change and
Cardiovascular Disease Risk Factors in the Look AHEAD Study. Obesity: doi:
10.1038/oby.2012.33.
23. Goldberg RB, Temprosa M, Haffner S, Orchard TJ, Ratner RE, et al. (2009)
Effect of Progression From Impaired Glucose Tolerance to Diabetes on
Cardiovascular Risk Factors and Its Amelioration by Lifestyle and Metformin
Intervention. Diabetes Care 32: 726–732.
24. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP (2000) Insulin-resistant
prediabetic subjects have more atherogenic risk factors than insulin-sensitive
prediabetic subjects: implications for preventing coronary heart disease during
the prediabetic state. Circulation 101: 975–980.
25. Reddigan J, Riddell M, Kuk J (2012) The joint association of physical activity
and glycaemic control in predicting cardiovascular death and all-cause mortality
in the US population. Diabetologia 55: 632–635.
26. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA (2007) Muscle and Liver
Insulin Resistance Indexes Derived From the Oral Glucose Tolerance Test.
Diabetes Care 30: 89–94.
27. Linton MF, Fazio S (2003) A practical approach to risk assessment to prevent
coronary artery disease and its complications. Am J Cardiol 92: 19i–26i.
Insulin Sensitivity and Cardiovascular Risk
PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e3926028. DeFronzo RA, Abdul-Ghani M (2011) Assessment and treatment of cardiovas-
cular risk in prediabetes: impaired glucose tolerance and impaired fasting
glucose. Am J Cardiol 108: 3B–24B.
29. Ray KK, Sattar N (2009) Diabetes: Which risk engines should be used to assess
patients with diabetes? Nat Rev Endocrinol 5: 302–303.
30. Chamnan P, Simmons R, Sharp S, Griffin S, Wareham N (2009) Cardiovascular
risk assessment scores for people with diabetes: a systematic review. Diabetologia
52: 2001–2014.
31. Kengne A, Patel A, Colagiuri S, Heller S, Hamet P, et al. (2010) The
Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do
not reliably estimate the probability of cardiovascular events in a large ethnically
diverse sample of patients with diabetes: the Action in Diabetes and Vascular
Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE)
Study. Diabetologia 53: 821–831.
Insulin Sensitivity and Cardiovascular Risk
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e39260